- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | Cognition Therapeutics plant entscheidende Studie für Demenz-Wirkstoff | 2 | Investing.com Deutsch | ||
| 31.03. | Cognition Therapeutics plans late-stage trial for dementia drug | 1 | Investing.com | ||
| 31.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics CEO Issues Letter to Shareholders | 251 | GlobeNewswire (Europe) | Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE... ► Artikel lesen | |
| 26.03. | Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial | 4 | Investing.com | ||
| 26.03. | COGNITION THERAPEUTICS INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 26.03. | Cognition Therapeutics: Verlust reduziert, Fokus auf Studie zu Lewy-Körper-Demenz | 1 | Investing.com Deutsch | ||
| 26.03. | COGNITION THERAPEUTICS INC - 10-K, Annual Report | 1 | SEC Filings | ||
| COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.03. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 26.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update | 571 | GlobeNewswire (Europe) | -Advancing zervimesine clinical development in DLB psychosis - - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y.,... ► Artikel lesen | |
| 26.03. | Cognition Therapeutics GAAP EPS of -$0.32 beats by $0.07 | 1 | Seeking Alpha | ||
| 23.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results | 1 | GlobeNewswire (USA) | ||
| 17.03. | Cognition Therapeutics präsentiert positive Studiendaten zum Demenz-Wirkstoff Zervimesine | 1 | Investing.com Deutsch | ||
| 17.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 | 2 | GlobeNewswire (USA) | ||
| 02.03. | Cognition Therapeutics shifts focus to DLB psychosis treatment | 1 | Investing.com | ||
| 02.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis | 281 | GlobeNewswire (Europe) | PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders... ► Artikel lesen | |
| 02.03. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Cognition Therapeutics, Inc.: Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies | 3 | GlobeNewswire (USA) | ||
| 27.01. | Cognition Therapeutics bespricht mit FDA nächste Studienphase für Demenz-Medikament | 1 | Investing.com Deutsch | ||
| 27.01. | Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug | 2 | Investing.com | ||
| 27.01. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,30 | -2,46 % | BioNTech, Shell, Zweistellige Inflationsrate? Das 4investors.de-Weekend | Welche Themen haben Anleger bewegt? Hier sind die 4investors.de-Berichte vom Wochenende von BioNTech über Shell bis zu einer aktuellen Marktanalyse mit Fokus auf die Folgen des Iran-Kriegs. BioNTech-Wirkstoff... ► Artikel lesen | |
| AMGEN | 301,95 | +0,03 % | Zai Lab (ZLAB), Amgen (AMGN) Partner to Evaluate Combination Lung Cancer Therapy | ||
| NOVAVAX | 7,520 | +0,13 % | Is Shah Capital's Criticism of Novavax Fair? A Wall Street Analyst Weighs In | ||
| BIOGEN | 149,64 | -0,69 % | Notable analyst calls this week: Tesla, Qualcomm and Biogen among top picks | ||
| VIKING THERAPEUTICS | 29,800 | -0,33 % | Better Long-Term Buy: Eli Lilly or Viking Therapeutics? | ||
| MAINZ BIOMED | 0,487 | -3,45 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| INTELLIA THERAPEUTICS | 12,460 | -1,89 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 46,900 | -1,21 % | Here's What TD Cowen Thinks About Tempus AI Inc (TEM) Stock | ||
| BIOCRYST PHARMACEUTICALS | 7,940 | -1,59 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report First Quarter 2026 Financial Results on May 6 | ||
| BIOMARIN PHARMACEUTICAL | 45,660 | 0,00 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,960 | -1,86 % | H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target | ||
| EXELIXIS | 38,160 | +0,03 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,458 | +1,78 % | PacBio Stock Up on New FFPE Workflow Boosting Cancer Sequencing | ||
| CARDIOL THERAPEUTICS | 1,154 | -9,98 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
17.04.2026 / 15:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart announces $25M share purchase agreement |
COGNITION THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,190 Euro und damit +7,21 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COGNITION THERAPEUTICS INC finden Sie auf Wallstreet Online.